Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04858776 · ClinicalTrials.gov registry record · Phase 2
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
A Phase 2 study of Iliofemoral; Thrombosis, sponsored by Mercator MedSystems.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 15
- Study locations
NCT04858776: Recruiting Phase 2 study of Iliofemoral; Thrombosis, sponsored by Mercator MedSystems.
NCT04858776 is a Phase 2 study of Iliofemoral; Thrombosis that is actively recruiting participants, run by Mercator MedSystems. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04858776, a Phase 2 study of Iliofemoral; Thrombosis, is actively recruiting participants, sponsored by Mercator MedSystems.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.
Primary Outcome
Freedom from loss of patency with associated symptoms
Conditions Studied
Interventions
- COMBINATION_PRODUCT Perivascular dexamethasone
- COMBINATION_PRODUCT Perivascular sham
Study Locations (15)
Texas
- CardioVoyage - Denison
- University of Texas, Houston - Houston
Other
- Galway University Hospital - Galway
- Guy's and St. Thomas Hospital - London
Connecticut
- Vascular Care Connecticut - Darien
Florida
- University of South Florida - Tampa
Illinois
- Northwestern University Hospital - Chicago
Louisiana
- CIS Clinical Research - Houma
Maryland
- Medstar Health Research Institute - Hyattsville
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT04858776 shows while recruiting
NCT04858776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Iliofemoral; Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Perivascular dexamethasone is the first listed.
NCT04858776 lists 15 locations in 13 states (Texas, Other, Connecticut).
Frequently Asked Questions
What is clinical trial NCT04858776 about?
NCT04858776 is a clinical study titled "Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT". This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptom...
What is the current status of trial NCT04858776?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-08-08. Estimated completion is 2026-12-31.
What conditions does trial NCT04858776 study?
This clinical trial studies the following conditions: Iliofemoral; Thrombosis.
What interventions are being tested in trial NCT04858776?
The interventions under investigation include: Perivascular dexamethasone (COMBINATION_PRODUCT), Perivascular sham (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04858776?
This trial is sponsored by Mercator MedSystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04858776 being conducted?
This trial has 15 study locations across Connecticut, Florida, Illinois, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iliofemoral; Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04858776's enrollment target sits among peer trials
60 1027th of 2000 higher than 869 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI